Our study is one of the largest population-based real-world cohorts, with 131 patients with EGFR and HER2 ex20ins-mutated advanced/metastatic NSCLC studied over a 6-year time span. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.